Bayforest Capital Ltd Trims Stock Holdings in Boston Scientific Corporation $BSX

Bayforest Capital Ltd reduced its stake in Boston Scientific Corporation (NYSE:BSX) by 34.4% during the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 370 shares of the medical equipment provider’s stock after selling 194 shares during the quarter. Bayforest Capital Ltd’s holdings in Boston Scientific were worth $37,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also made changes to their positions in the company. 1248 Management LLC purchased a new stake in shares of Boston Scientific in the first quarter valued at $26,000. Y.D. More Investments Ltd purchased a new stake in shares of Boston Scientific in the first quarter valued at $27,000. Investment Management Corp VA ADV purchased a new stake in shares of Boston Scientific in the fourth quarter valued at $25,000. Sunbeam Capital Management LLC purchased a new stake in shares of Boston Scientific in the fourth quarter valued at $26,000. Finally, Ameriflex Group Inc. purchased a new position in Boston Scientific during the fourth quarter worth about $31,000. 89.07% of the stock is currently owned by hedge funds and other institutional investors.

Boston Scientific Stock Performance

Boston Scientific stock opened at $102.71 on Friday. The stock’s 50-day moving average is $104.86 and its 200-day moving average is $102.26. The company has a market cap of $152.19 billion, a price-to-earnings ratio of 61.14, a price-to-earnings-growth ratio of 2.51 and a beta of 0.65. The company has a debt-to-equity ratio of 0.49, a current ratio of 1.37 and a quick ratio of 0.82. Boston Scientific Corporation has a 12 month low of $80.64 and a 12 month high of $109.50.

Boston Scientific (NYSE:BSX) last released its quarterly earnings data on Wednesday, July 23rd. The medical equipment provider reported $0.75 EPS for the quarter, topping analysts’ consensus estimates of $0.72 by $0.03. The company had revenue of $5.06 billion for the quarter, compared to the consensus estimate of $4.89 billion. Boston Scientific had a return on equity of 19.21% and a net margin of 13.55%.The company’s quarterly revenue was up 22.8% compared to the same quarter last year. During the same period last year, the business posted $0.62 EPS. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. Equities analysts anticipate that Boston Scientific Corporation will post 2.85 earnings per share for the current year.

Insider Buying and Selling

In other news, EVP Arthur C. Butcher sold 17,313 shares of the stock in a transaction dated Friday, August 1st. The stock was sold at an average price of $104.63, for a total value of $1,811,459.19. Following the completion of the sale, the executive vice president owned 23,600 shares in the company, valued at approximately $2,469,268. This trade represents a 42.32% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Joseph Michael Fitzgerald sold 50,000 shares of the stock in a transaction dated Tuesday, September 2nd. The shares were sold at an average price of $105.43, for a total value of $5,271,500.00. Following the completion of the sale, the executive vice president owned 178,342 shares of the company’s stock, valued at approximately $18,802,597.06. This trade represents a 21.90% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 174,214 shares of company stock worth $18,397,457 in the last ninety days. 0.50% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

BSX has been the topic of several recent analyst reports. Truist Financial increased their target price on Boston Scientific from $120.00 to $125.00 and gave the stock a “buy” rating in a research report on Thursday, July 24th. Needham & Company LLC reiterated a “buy” rating and set a $121.00 target price on shares of Boston Scientific in a research report on Thursday. Barclays increased their target price on Boston Scientific from $125.00 to $133.00 and gave the stock an “overweight” rating in a research report on Thursday, July 24th. Oppenheimer upgraded Boston Scientific from a “market perform” rating to an “outperform” rating and increased their target price for the stock from $118.00 to $125.00 in a research report on Monday, September 8th. Finally, Citigroup reiterated a “buy” rating and set a $125.00 target price (up from $119.00) on shares of Boston Scientific in a research report on Thursday, May 22nd. Three investment analysts have rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and one has assigned a Hold rating to the stock. According to MarketBeat, Boston Scientific currently has an average rating of “Buy” and a consensus target price of $118.04.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.